Pharmafile Logo
Pharmafocus logo
Advanced Search
biogen_logo

Biogen reports on Tecfidera multiple sclerosis clinical trials

October 9, 2015
Research and Development

Biogen has presented data demonstrating the efficacy and safety of Tecfidera (dimethyl fumarate) across a broad range of people with …

News
sativex

Almirall presents new data on cannabinoid-based MS treatment

October 9, 2015
Research and Development Almirall, multiple sclerosis

Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, …

News
guido_rasi

EMA appoints Guido Rasi as executive director

October 9, 2015
Medical Communications, Sales and Marketing EMA, Guido Rasi

The European Medicines Agency’s (EMA’s) Management Board has nominated Professor Guido Rasi as the Executive Director of the Agency. The …

Appointment
money_pills

Oncology groups and doctors fight for lower-priced cancer treatments

October 9, 2015
Medical Communications, Research and Development, Sales and Marketing

Oncology groups such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) are working …

News
sanofi_olivier_brandicourt

Sanofi looks to increase productivity in France by 25%

October 9, 2015
Manufacturing and Production, Medical Communications Sanofi

Sanofi is looking for a deal with unions in order to boost productivity by 20-25% at French plants over three …

News
merckincweb2

Merck announces positive Elbasvir/Grazoprevir trial results

October 9, 2015
Research and Development

Merck has announced the publication of results from C-SURFER, the first Phase III clinical trial to investigate an all-oral, ribavirin-free …

News
astrazeneca_plaque

AstraZeneca’s Moventig now available through NHS

October 9, 2015
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, moventig

AstraZeneca has announced that Moventig (naloxegol) has been made available for adult patients with opioid-induced constipation (OIC) in England and …

News
bronchial_thermoplasty

Taking on IFP, COPD and severe asthma: ERS 2015 roundup

October 9, 2015
Medical Communications, Research and Development

Leading pharmaceutical companies, physicians, healthcare professionals, scientists, respiratory experts, and of course the media, including Pharmafocus, gathered in Amsterdam at the …

Feature
dr_jerome_b_zeldis

Ovid Therapeutics appoints Dr Jerome B. Zeldis to Its Scientific Advisory Board

October 9, 2015
Medical Communications

Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, has …

Appointment
Genentech logo

Positive late-stage results for Genentech’s ocrelizumab in different forms of MS

October 8, 2015
Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab

Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …

News
obesity

Innovative pipeline can transform obesity treatment, says GBI Research

October 8, 2015
Research and Development obesity

While the current obesity treatment market has a high level of unmet need, the therapeutic landscape could be transformed by …

News
troponin_blood_test

Simple blood test can accurately predict imminent heart attacks

October 8, 2015
Research and Development NHS, heart attack

A simple blood test which predicts whether a patient suffering chest pains will have a heart attack has the potential to save …

News
Gilenya

Novartis looks to new measure of Gilenya outcomes

October 8, 2015
Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis

Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …

News

UCB plots new Vimpat submissions after positive monotherapy results

October 8, 2015
Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments.  …

News
Genzyme

Genzyme’s Lemtrada shows five-year efficacy in extended trials

October 8, 2015
Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …

News
Nobel Prize

Infectious diseases dominate Nobel Prize awards for medicine

October 8, 2015
Manufacturing and Production, Research and Development Nobel Prize, artemisinin, ivermectin, malaria, mectizan, river blindness

Pharma researchers have been awarded the 2015 Nobel Prize for their work on a river blindness treatment, along with work …

News
ms_symptoms

Multiple Sclerosis treatment will be a $20bn market by 2024

October 7, 2015
Research and Development multiple sclerosis

The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …

News
ms_early_intervention

Experts call for greater urgency in MS treatment

October 7, 2015
Research and Development multiple sclerosis

A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …

News
ferring_president

PROFILE: Ambitious Ferring wants to be global fertility leader

October 7, 2015
Manufacturing and Production, Research and Development Ferring, peptides

The stunning view of the Alps across Lake Geneva from Ferring’s corporate headquarters in Saint-Prex seems appropriate for a company …

Feature
amerisourcebergen

AmerisourceBergen acquires sterile compounder PharMEDium for $2.5bn

October 7, 2015
Research and Development, Sales and Marketing AmerisourceBergen, mergers and acquisitions

AmerisourceBergen will now source compounded drugs for its hospital clients by manufacturing them itself after spending more than $2.5 billion …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026